rs3092994

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_007294.4(BRCA1):​c.5152+66G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.333 in 1,326,596 control chromosomes in the GnomAD database, including 76,364 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.31 ( 7707 hom., cov: 32)
Exomes 𝑓: 0.34 ( 68657 hom. )

Consequence

BRCA1
NM_007294.4 intron

Scores

2

Clinical Significance

Benign reviewed by expert panel B:18O:2

Conservation

PhyloP100: -0.517
Variant links:
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.77).
BP6
Variant 17-43063808-C-T is Benign according to our data. Variant chr17-43063808-C-T is described in ClinVar as [Benign]. Clinvar id is 55428.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr17-43063808-C-T is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.476 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRCA1NM_007294.4 linkc.5152+66G>A intron_variant Intron 17 of 22 ENST00000357654.9 NP_009225.1 P38398-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRCA1ENST00000357654.9 linkc.5152+66G>A intron_variant Intron 17 of 22 1 NM_007294.4 ENSP00000350283.3 P38398-1

Frequencies

GnomAD3 genomes
AF:
0.311
AC:
47165
AN:
151838
Hom.:
7704
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.232
Gnomad AMI
AF:
0.286
Gnomad AMR
AF:
0.272
Gnomad ASJ
AF:
0.358
Gnomad EAS
AF:
0.372
Gnomad SAS
AF:
0.494
Gnomad FIN
AF:
0.404
Gnomad MID
AF:
0.357
Gnomad NFE
AF:
0.332
Gnomad OTH
AF:
0.328
GnomAD4 exome
AF:
0.336
AC:
394441
AN:
1174640
Hom.:
68657
AF XY:
0.342
AC XY:
204021
AN XY:
596304
show subpopulations
Gnomad4 AFR exome
AF:
0.229
AC:
6310
AN:
27540
Gnomad4 AMR exome
AF:
0.221
AC:
9396
AN:
42454
Gnomad4 ASJ exome
AF:
0.366
AC:
8835
AN:
24166
Gnomad4 EAS exome
AF:
0.353
AC:
13419
AN:
38044
Gnomad4 SAS exome
AF:
0.499
AC:
39345
AN:
78906
Gnomad4 FIN exome
AF:
0.397
AC:
20876
AN:
52636
Gnomad4 NFE exome
AF:
0.324
AC:
277326
AN:
855082
Gnomad4 Remaining exome
AF:
0.336
AC:
17019
AN:
50674
Heterozygous variant carriers
0
13307
26614
39920
53227
66534
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Exome Het
Exome Hom
Variant carriers
0
8070
16140
24210
32280
40350
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.311
AC:
47186
AN:
151956
Hom.:
7707
Cov.:
32
AF XY:
0.316
AC XY:
23462
AN XY:
74230
show subpopulations
Gnomad4 AFR
AF:
0.232
AC:
0.232043
AN:
0.232043
Gnomad4 AMR
AF:
0.272
AC:
0.271661
AN:
0.271661
Gnomad4 ASJ
AF:
0.358
AC:
0.358131
AN:
0.358131
Gnomad4 EAS
AF:
0.371
AC:
0.37118
AN:
0.37118
Gnomad4 SAS
AF:
0.493
AC:
0.492946
AN:
0.492946
Gnomad4 FIN
AF:
0.404
AC:
0.404292
AN:
0.404292
Gnomad4 NFE
AF:
0.332
AC:
0.332058
AN:
0.332058
Gnomad4 OTH
AF:
0.332
AC:
0.331754
AN:
0.331754
Heterozygous variant carriers
0
1629
3259
4888
6518
8147
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Genome Het
Genome Hom
Variant carriers
0
492
984
1476
1968
2460
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.306
Hom.:
3176
Bravo
AF:
0.292
Asia WGS
AF:
0.414
AC:
1438
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:18Other:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 1 Benign:6Other:1
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
GreenArray Genomic Research & Solutions of Accurate Diagnostic Private Limited
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 21, 2015
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 09, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 12, 2015
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.3304 (Asian), 0.2154 (African), 0.3615 (European), derived from 1000 genomes (2012-04-30). -

-
Breast Cancer Information Core (BIC) (BRCA1)
Significance:not provided
Review Status:no classification provided
Collection Method:clinical testing

- -

Sep 06, 2017
Counsyl
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:4
Nov 09, 2016
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not provided Benign:3
Aug 16, 2022
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 32846166, 30713775, 26092435, 27884173, 15564800) -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Hereditary cancer-predisposing syndrome Benign:3
Dec 11, 2019
Sema4, Sema4
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Dec 10, 2014
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 18, 2014
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Hereditary breast ovarian cancer syndrome Benign:2
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial cancer of breast Other:1
-
Genomic Research Center, Shahid Beheshti University of Medical Sciences
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.77
CADD
Benign
11
DANN
Benign
0.46
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=62/38
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs3092994; hg19: chr17-41215825; COSMIC: COSV58793783; COSMIC: COSV58793783; API